Levosimendan Kabi

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Kabi (Levosimendan)

Q: What is Levosimendan Kabi used for?

Levosimendan Kabi is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure. It helps improve cardiac contractility and reduces vascular resistance, supporting patients who are experiencing sudden worsening of heart failure symptoms.

Q: How does levosimendan work?

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering the heart's after‑load.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The medication is administered intravenously under continuous monitoring, and the exact infusion rate and duration are individualized for each patient.

Q: Is levosimendan safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Levosimendan Kabi from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and after‑load‑reducing effect that can be advantageous in certain heart‑failure scenarios.

Q: What are the storage and handling requirements for Levosimendan Kabi?

Levosimendan Kabi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, the solution should be inspected for particulate matter and discoloration, and any deviation from recommended storage conditions should be reported.

Q: How is Levosimendan administered?

Levosimendan is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a monitored setting such as an intensive care unit, with regular assessment of blood pressure, heart rate, and cardiac rhythm.

Q: What are the most serious risks associated with levosimendan?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous hemodynamic monitoring is essential during infusion to detect and manage these potential complications promptly.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), mechanical obstruction of the outflow tract, or known hypersensitivity to the drug. Caution is also advised in individuals with significant hepatic or renal impairment, and the decision to treat should be individualized by the physician.

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as an injectable solution for intravenous use. It is employed to improve cardiac performance in patients with acute decompensated heart failure.
GNH India supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Fresenius Kabi Austria Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of heart failure syndromes where enhanced contractility and vasodilation are required.
Acute decompensated heart failure: improves cardiac output and relieves congestion.
Chronic heart failure with low output: provides inotropic support as an adjunct to standard therapy.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation and reducing cardiac after‑load.

Side Effects

Levosimendan may be associated with several adverse reactions.

Common Side Effects

Headache: mild to moderate intensity.
Hypotension: transient drop in blood pressure.
Nausea or vomiting: gastrointestinal discomfort.
Dizziness: related to blood pressure changes.
Tachycardia: increased heart rate.
Arrhythmias: occasional premature beats.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular arrhythmias: potentially life‑threatening.
Myocardial ischemia: chest pain or ECG changes.
Allergic reactions: rash, pruritus, or anaphylaxis.
Hepatic enzyme elevation: abnormal liver function tests.
Thrombocytopenia: reduced platelet count.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures.

Blood pressure monitoring: watch for hypotension during infusion.
Cardiac rhythm surveillance: observe for arrhythmias.
Contraindication in severe hypotension: avoid use when systolic BP <90 mmHg.
Adjust in renal/hepatic impairment: dose may need modification.
Caution with mechanical obstruction: do not use in patients with outflow tract obstruction.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Levosimendan can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

Concurrent strong vasodilators (e.g., nitroglycerin): risk of profound hypotension.
Other inotropic agents (e.g., dobutamine): may precipitate arrhythmias.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt inotropic response.
ACE inhibitors or ARBs: additive blood‑pressure lowering effect.
Diuretics: can exacerbate volume depletion.
Calcium channel blockers: may affect vascular tone.
CYP450 inhibitors (e.g., ketoconazole): potential increase in plasma levosimendan levels.

Frequently Asked Questions

Levosimendan Kabi is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure. It helps improve cardiac contractility and reduces vascular resistance, supporting patients who are experiencing sudden worsening of heart failure symptoms.

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering the heart's after‑load.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The medication is administered intravenously under continuous monitoring, and the exact infusion rate and duration are individualized for each patient.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and after‑load‑reducing effect that can be advantageous in certain heart‑failure scenarios.

Levosimendan Kabi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, the solution should be inspected for particulate matter and discoloration, and any deviation from recommended storage conditions should be reported.

Levosimendan is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a monitored setting such as an intensive care unit, with regular assessment of blood pressure, heart rate, and cardiac rhythm.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous hemodynamic monitoring is essential during infusion to detect and manage these potential complications promptly.

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), mechanical obstruction of the outflow tract, or known hypersensitivity to the drug. Caution is also advised in individuals with significant hepatic or renal impairment, and the decision to treat should be individualized by the physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.